Protein specialist Prothena (Nasdaq: PRTA) is to receive $80 million from Bristol Myers Squibb (NYSE: BMY) after the New York-based firm opted in on a program in Alzheimer’s.
The money brings to $230 million the total BMS has paid under the collaboration, with up to around $2 billion more on the line for rights, milestone payments and royalties, in the best case scenario.
The global dementia research community has been given a shot in the arm by the recent approval of Biogen’s (Nasdaq: BIIB) Aduhelm (aducanumab), the first new Alzheimer’s therapy in decades.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze